Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Orthofix Medical ( (OFIX) ) is now available.
On February 24, 2026, Orthofix reported fourth-quarter 2025 net sales of $219.9 million, or $218.6 million excluding discontinued M6 disc lines, marking modest reported growth but stronger constant-currency gains, alongside an improved gross margin and a sharply reduced net loss of $2.2 million. The company posted its eighth straight quarter of adjusted EBITDA growth, generated $16.8 million of free cash flow in the quarter and slightly positive free cash flow for 2025, and highlighted double-digit Global Spine Fixation and robust Bone Growth Therapies and U.S. Limb Reconstruction growth as it issued 2026 guidance and signaled confidence in sustained margin expansion and cash generation.
Management emphasized that optimization of the spine commercial channel, accelerating adoption of enabling technologies, and new or expanded offerings such as TRUELOK Elevate, FITBONE and the planned second-half 2026 full launch of VIRATA are expected to drive durable top-line gains. By reinforcing its Biologics portfolio and maintaining momentum in limb reconstruction and BGT, Orthofix positioned itself for continued operational improvement and long-term value creation for shareholders despite exiting the M6 product lines.
The most recent analyst rating on (OFIX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Orthofix Medical stock, see the OFIX Stock Forecast page.
Spark’s Take on OFIX Stock
According to Spark, TipRanks’ AI Analyst, OFIX is a Neutral.
Orthofix’s overall stock score is driven by mixed financial performance, with strong revenue growth but challenges in profitability and cash flow. Technical indicators are positive, supporting a favorable trend. The earnings call highlighted operational efficiency and growth, but valuation remains a concern due to ongoing losses.
To see Spark’s full report on OFIX stock, click here.
More about Orthofix Medical
Orthofix Medical Inc., based in Lewisville, Texas, is a global medical technology company focused on spine and orthopedics. Its portfolio includes spinal implants, biologics, enabling technologies such as 7D FLASH Navigation, and Bone Growth Therapies, as well as limb reconstruction systems like TRUELOK Elevate and FITBONE bone transport and lengthening nails, targeting surgeons and healthcare providers worldwide.
Average Trading Volume: 209,924
Technical Sentiment Signal: Sell
Current Market Cap: $544.9M
Learn more about OFIX stock on TipRanks’ Stock Analysis page.